Haemostatic measurements in childhood nephrotic syndrome

1991 ◽  
Vol 150 (5) ◽  
pp. 374-378 ◽  
Author(s):  
A. T. H. Elidrissy ◽  
M. B. Abdurrahman ◽  
H. M. Bahakim ◽  
M. D. Jones ◽  
A. M. A. Gader
Keyword(s):  
Nephrotic Syndrome ◽  
Childhood Nephrotic Syndrome

scholarly journals Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis

2021 ◽  
Author(s):  
Anne M. Schijvens ◽  
Nynke Teeninga ◽  
Eiske M. Dorresteijn ◽  
Steven Teerenstra ◽  
Nicholas J. Webb ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Steroid Treatment ◽  
First Episode ◽  
Childhood Nephrotic Syndrome ◽  
Steroid Sensitive Nephrotic Syndrome ◽  
Steroid Sensitive ◽  
First Relapse ◽  
Steroid Regimen

AbstractSteroids are the cornerstone of the treatment of childhood nephrotic syndrome. The optimal duration for the first episode remains a matter of debate. The aim of this study is to determine whether the 8 weeks International Study of Kidney Disease in Children (ISKDC) regimen is equally effective as the 12 weeks steroid regimen from the German society of pediatric nephrology (Arbeitsgemeinschaft für Pädiatrische Nephrologie [APN]). An individual patient data (IPD) meta-analysis of randomized controlled trials reporting on prednisolone treatment for a first episode of childhood nephrotic syndrome was conducted. European trials aimed at investigating the ISKDC and/or APN steroid regimen were selected. The lead investigators of the selected trials were requested to provide the IPD of the specific treatment groups. Four trials included European cohorts using dosing schedules according to the regimens studied. IPD of two trials were available. A significant difference was found in time to first relapse after cessation of steroid treatment between the 8 and 12 weeks treatment group with a median time to relapse of 29 and 63 days, respectively. Moreover, relapse rate ratios during total follow-up were 51% higher for the 8 weeks regimen. Finally, younger children have a significantly lower time to first relapse and frequently relapsing nephrotic syndrome.Conclusions: The results of this IPD meta-analysis suggest that the 8 weeks steroid regimen for a first episode of steroid-sensitive nephrotic syndrome may not be equally effective as the 12 weeks steroid regimen. Moreover, this study highlights the importance of using uniform definitions to enable accurate comparison and interpretation of trial results.Trial registration: Registration number: CRD42020199244, date of registration 16-08-2020 What is Known:• Steroids are the cornerstone of the treatment of childhood nephrotic syndrome, however the optimal duration for the first episode remains a matter of debate.• Currently, the 8 weeks ISKDC protocol and 12 weeks APN protocol are among the most frequently used protocols in Europe. What is New:• The 8 weeks steroid regimen for a first episode of steroid-sensitive nephrotic syndrome may not be equally effective as the 12 weeks steroid regimen for the treatment of a first episode of nephrotic syndrome.• Younger children have a significantly shorter time to first relapse and time to frequent relapsing nephrotic syndrome.

scholarly journals Management of idiopathic childhood nephrotic syndrome in sub-Saharan Africa: Ibadan consensus statement

2021 ◽  
Vol 99 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Christopher Esezobor ◽  
Adebowale D. Ademola ◽  
Adewale E. Adetunji ◽  
Emmanuel A. Anigilaje ◽  
Anthony Batte ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Consensus Statement ◽  
Sub Saharan Africa ◽  
Childhood Nephrotic Syndrome ◽  
Sub Saharan

scholarly journals Twenty-year follow-up of protective immunity of the Oka strain of live varicella vaccine recipients with childhood nephrotic syndrome

1994 ◽  
Vol 7 (2) ◽  
pp. 213-216
Author(s):  
Shigeru Minowa ◽  
Sachiko Takeichi ◽  
Yoshizo Asano ◽  
Takehiko Yasaki ◽  
Kazuo Tsuzuki ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Protective Immunity ◽  
Varicella Vaccine ◽  
Childhood Nephrotic Syndrome

scholarly journals Practice patterns and outcomes of repository corticotropin injection (Acthar® Gel) use in childhood nephrotic syndrome: A study of the North American Pediatric Renal Trials and collaborative studies and the Pediatric Nephrology Research Consortium

2021 ◽  
Vol 5 (2) ◽  
pp. 067-076
Author(s):  
Faizan Mohammed K ◽  
McCracken Courtney ◽  
Lieberman Kenneth ◽  
Leong Traci ◽  
Benfield Mark R
Keyword(s):  
Nephrotic Syndrome ◽  
Demographic Data ◽  
Pediatric Nephrology ◽  
Drug Regimen ◽  
Disease Response ◽  
Childhood Nephrotic Syndrome ◽  
The North ◽  
Set Up ◽  
Steroid Responsiveness ◽  
Active Disease

Objective: We set up a U.S. registry to examine prescription patterns and patient outcomes of repository corticotropin injection (Acthar® Gel) for childhood nephrotic syndrome. Methods: 18 participating U.S. pediatric centers performed retrospective review and prospective observation of patients < 21 years old with nephrotic syndrome treated with Acthar Gel. We captured baseline characteristics, drug regimen and duration, and disease response following treatment. Results: 46 patients, enrolled from 2015 to 2020 were included. 27 (58.7%) were male. 18 patients (39.1%) had a diagnosis of minimal change followed by focal segmental glomerulosclerosis in 16 patients (34.7%). Median age at start of treatment was 12.5 years (IQR 8.5-17.4) compared to 5.3 years at diagnosis (IQR 2.7-10.5 years). 52% were resistant to corticosteroids. The most common Acthar Gel regimen was 80IU twice a week with a median duration of 199 days (IQR 88-365). Among 37 patients with active disease, 18 (49%) were able to achieve partial or complete remission, though all patients that had a positive response were on other immunosuppressants concomitantly. Conclusion: We report the findings of the largest registry cohort of pediatric patients in the U.S. treated with Acthar Gel for clinically challenging cases of nephrotic syndrome. Acthar Gel was successful in inducing remission in approximately half of the patients with active disease at time of treatment. No predictors of response with respect to demographic data, age at start of Acthar Gel therapy, etiology of nephrotic syndrome, presence or absence of comorbidities, or steroid responsiveness was noted.

scholarly journals Clinical and Biochemical Evaluation of Atypically Presented Childhood Nephrotic Syndrome

1970 ◽  
Vol 21 (1) ◽  
pp. 56-61 ◽  
Author(s):  
Nasir Uddin Mahmud ◽  
Jhulan Das Sharma ◽  
Abul Kalam Azad ◽  
Chowdhury Chimnjib Barua ◽  
Abu Hena Mostafa Kamal
Keyword(s):  
Nephrotic Syndrome ◽  
Key Words ◽  
College Teachers ◽  
Childhood Nephrotic Syndrome ◽  
Medical College ◽  
Biochemical Evaluation

Key words: nephrotic syndrome; proteinuria; oedemaDOI: 10.3329/jcmcta.v21i1.7680 Journal of Chittagong Medical College Teachers' Association 2010: 21(1):56-61

scholarly journals P-glycoprotein and/or Histone Deacetylase 2 Regulates Steroid Responsiveness in Childhood Nephrotic Syndrome

2020 ◽  
Vol 15 (1) ◽  
pp. 5
Author(s):  
Vikas Agarwal ◽  
Harshit Singh ◽  
Narayan Prasad ◽  
DurgaPrasanna Misra ◽  
AkhileshKumar Jaiswal
Keyword(s):  
Nephrotic Syndrome ◽  
Histone Deacetylase ◽  
Histone Deacetylase 2 ◽  
Childhood Nephrotic Syndrome ◽  
P Glycoprotein ◽  
Steroid Responsiveness

Comparison of second-line immunosuppressants for childhood refractory nephrotic syndrome: a systematic review and network meta-analysis

2016 ◽  
Vol 65 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Hai-Dong Fu ◽  
Gu-Ling Qian ◽  
Zheng-yang Jiang
Keyword(s):  
Nephrotic Syndrome ◽  
Mycophenolate Mofetil ◽  
Meta Analysis ◽  
Immunosuppressive Agents ◽  
Second Line ◽  
Childhood Nephrotic Syndrome ◽  
Randomized Controlled ◽  
Search Terms ◽  
October 17 ◽  
Refractory Nephrotic Syndrome

Although, most patients respond initially to therapy for nephrotic syndrome, about 70% of patients have a relapse. Currently, there is no consensus about the most appropriate second-line agent in children who continue to suffer a relapse. This network meta-analysis was designed to compare the efficacy and safety of the commonly used immunosuppressive agents in second-line therapeutic agents (ie, cyclophosphamide, cyclosporine, tacrolimus and mycophenolate mofetil) for refractory childhood nephrotic syndrome. MEDLINE, Cochrane, EMBASE and Google Scholar databases were searched until October 17, 2015 using the following search terms: cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil and childhood nephrotic syndrome. Randomized controlled trials, prospective 2-arm studies and cohort studies were included. 7 studies with 391 patients were included. Bayesian network meta-analysis found that treatment with mycophenolate mofetil had the greatest odds of relapse compared with tacrolimus (pooled OR=49.72, 95% credibility interval (CrI) 1.65 to 2483.32), cyclophosphamide (pooled OR=72.05, 95% CrI 1.44 to 13633.33) and cyclosporine (pooled OR=11.42, 95% CrI 1.03 to 131.60). Rank probability analysis found cyclophosphamide was the best treatment with the lowest relapse rate as compared with other treatments (rank probability=0.58), and tacrolimus was ranked as the second best (rank probability=0.38). Our findings support the use of cyclophosphamide and tacrolimus in treating children with relapsing nephrotic syndrome.

Sign in / Sign up

Export Citation Format

Share Document